GlassScriptPhysician profile
Samuel Shoptaw
NPI 1245949239
$1,553.24
in general payments reported to CMS, 2019-2025
27 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $451 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $188.00 | 2024-2025 | Rystiggo, Nayzilam, Briviact |
| Catalyst Pharmaceuticals, INC. | $177.41 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $129.25 | 2024-2025 | Ultomiris |
| Eisai INC. | $129.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.48 | 2024-2025 | Hyqvia |
| Neurelis, INC. | $71.79 | 2024-2025 | Valtoco |
| Emd Serono, INC. | $69.26 | 2024-2025 | |
| Csl Behring | $64.02 | 2025 | Hizentra |
| Lilly USA, LLC | $60.29 | 2024-2025 | Amyvid, Kisunla |
| Sk Life Science, INC. | $58.59 | 2024-2025 | |
| Medtronic, INC. | $57.09 | 2025 | Duet |
| Springworks Therapeutics, INC. | $49.94 | 2025 | Gomekli |
| Vertex Pharmaceuticals Incorporated | $45.59 | 2025 | |
| Tg Therapeutics, INC. | $42.26 | 2024-2025 | |
| Argenx US, INC. | $35.33 | 2025 | Vyvgart Hytrulo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $31.89 | 2025 | |
| Pfizer INC. | $30.72 | 2025 | |
| C2n Diagnostics, LLC | $27.53 | 2025 | Precivityad2 |
| Banner Life Sciences, LLC | $25.37 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.90 | 2025 | Onpattro |
| Smith+Nephew, INC. | $21.87 | 2025 | Pico 7, Pico 14 |
| Acadia Pharmaceuticals INC | $17.38 | 2025 | Nuplazid |
| Ipsen Biopharmaceuticals, INC | $17.18 | 2025 | Dysport |
| Lundbeck LLC | $16.41 | 2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $15.40 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.61 | 2024 | Andexxa |
| Boston Scientific Corporation | $13.61 | 2025 | General - Dbs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Shoptaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.